EC Number   |
Activating Compound |
Reference |
|---|
   1.1.1.50 | 1-butyl-3-methylimidazolium L-lactate |
activates the enzyme as 5% co-solvent in Tris-HCl buffer, overview |
674981 |
| 1.1.1.50 | 1-butyl-3-methylimidazolium L-lactate |
enhanced activity of 3alpha-hydroxysteroid dehydrogenase by addition of the co-solvent to 50 mM Tris-HCl buffer in aqueous phase of biphasic systems for reductive production of steroids. In a coupled-enzyme system comprising HSDH and formate dehydrogenase, a twofold increase in production rate of androsterone is obtained when utilizing 1-butyl-3-methylimidazolium L-lactate with NADH regeneration, overview |
674981 |
| 1.1.1.50 | 1-ethyl-3-methylimidazolium trifluoromethanesulfonate |
addition of the co-solvent leads to slightly enhanced enzyme activity n an aqueous-organic solvent system with Tris-HCl buffer, overview |
674981 |
| 1.1.1.50 | fluoxetine |
activates allopregnanolone formation in vivo, not in vitro at a concentration up to 0.05 mM, therefore in vivo activation is probably not realized by enzyme activation but a different mechanism |
654626 |
| 1.1.1.50 | more |
no in vitro activation by paroxetine, sertraline, norfluoxetine, carbamazepine, clozapine, flurbiprofen, and sulfobromophthalein at a concentration up to 0.05 mM |
654626 |
| 1.1.1.50 | more |
poor activation by 1-butyl-3-methylimidazolium trifluoromethanesulfonate and 1-butyl-3-methylimidazolium tetrafluoroborate |
674981 |
| 1.1.1.50 | more |
the expression of 3alpha-HSD/CR is induced by 0.5 mM testosterone |
697268 |
| 1.1.1.50 | more |
treatment with 0.002 mM T0901317 induces about 2fold AKR1C4 mRNA expression, liver X receptor alpha mediates transcriptional activation of the AKR1C4 gene, leading to increased AKR1C4 protein expression |
689076 |
